Abstract | BACKGROUND: METHODS: A total of 132 patients who met the DSM-IV criteria for major depressive disorder were enrolled in the study. 54 of these patients were male and 78 were female (age range, 20-74years; mean±S.D., 51±15). The patients' clinical improvement was evaluated using the 17-item Hamilton Rating Scale for Depression (HAMD-17) before (T0) and at 8weeks after the administration of SSRI treatment (T8). Patients with at least a 50% decrease in the HAMD-17 score were classified as responders. RESULTS: No correlation was observed between the BDNF Val66Met polymorphism and response to SSRIs or between the BDNF Val66Met polymorphism and serum BDNF levels at T0. An inverse correlation was found between serum BDNF levels and HAMD-17 scores at T0. CONCLUSIONS: These results suggest that the BDNF Val66Met polymorphism is independent of both the response to SSRI treatment and serum BDNF levels. The findings in the present study reconfirm that the serum BDNF level is a state biomarker for depression.
|
Authors | Reiji Yoshimura, Taro Kishi, Akihito Suzuki, Wakako Umene-Nakano, Atsuko Ikenouchi-Sugita, Hikaru Hori, Koichi Otani, Nakao Iwata, Jun Nakamura |
Journal | Progress in neuro-psychopharmacology & biological psychiatry
(Prog Neuropsychopharmacol Biol Psychiatry)
Vol. 35
Issue 4
Pg. 1022-5
(Jun 01 2011)
ISSN: 1878-4216 [Electronic] England |
PMID | 21338649
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2011 Elsevier Inc. All rights reserved. |
Chemical References |
- Biomarkers
- Brain-Derived Neurotrophic Factor
- Serotonin Uptake Inhibitors
- Paroxetine
- Sertraline
|
Topics |
- Adult
- Aged
- Asian People
- Biomarkers
- Brain-Derived Neurotrophic Factor
(blood, genetics)
- Depressive Disorder
(drug therapy, genetics, psychology)
- Diagnostic and Statistical Manual of Mental Disorders
- Female
- Heterozygote
- Humans
- Logistic Models
- Male
- Middle Aged
- Paroxetine
(pharmacology)
- Polymorphism, Genetic
(genetics)
- Psychiatric Status Rating Scales
- Selective Serotonin Reuptake Inhibitors
(pharmacology)
- Sertraline
(pharmacology)
- Young Adult
|